Comparison · NCT02931539-e8eca7b4
Investigator-assigned Anti-CMV Treatment (IAT) vs Maribavir 400 mg: Number of Participants With All-cause Mortality by the End of the Study
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Investigator-assigned Anti-CMV Treatment (IAT) vs Maribavir 400 mg: Number of Participants With All-cause Mortality by the End of the Study. Trial comparisons, record NCT02931539-e8eca7b4. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02931539-e8eca7b4
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.111 | 0.0661 | 0.181 | wilson | |
| Risk in group 2 | 0.115 | 0.0802 | 0.162 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00378 | -0.0689 | 0.0741 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.967 | 0.518 | 1.8 | log | |
| Odds ratio, group 1 over group 2 | 0.963 | 0.477 | 1.94 | log | |
| Number needed to treat, for one fewer participant with the outcome on Investigator-assigned Anti-CMV Treatment (IAT) than on Maribavir 400 mg | 264 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Investigator-assigned Anti-CMV Treatment (IAT) | Participants received 1 or 2 of the 4 anti-CMV agents from the following: ganciclovir, valganciclovir, foscarnet, or cidofovir based on the investigator's discretion for the 8 week treatment period. | 13 | 117 | OG000 |
| Group 2 | Maribavir 400 mg | Participants received maribavir 400 mg (2\*200 mg tablets), orally, twice daily for the 8 week treatment period. | 27 | 235 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With All-cause Mortality by the End of the Study
- Description
All-cause mortality was analyzed by the end of study regardless of the use of rescue treatment or alternative anti-CMV treatment. Number of participants who died during the entire study period were reported.
- Time frame
- From enrollment up to end of study (approximately 44 months)
- Population
- The randomized set consisted of all participants who had signed informed consent and had begun some study procedures and were randomized to the study.
Source ClinicalTrials.gov
Trial
- Title
Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
- NCT number
- NCT02931539
- Phases
- PHASE3
- Conditions
- Cytomegalovirus (CMV)
- Interventions
- Maribavir, Ganciclovir, Valganciclovir, Foscarnet, Cidofovir
- Lead sponsor
- Shire
- Results first posted
- 2021-09-23
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02931539?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02931539-e8eca7b4